rel="nofollow" href="#ulink_08d80d6e-25b9-5179-a3e3-70acf7e7c92c">5McManus JF, Davey RA, Maclean HE, Doust EA, Chiu WS, Sims NA, Bouxsein ML, Glatt V, Zajac JD, Danks JA: Intermittent Fugu parathyroid hormone 1 (1–34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. Bone 2008;42:1164–1174.
6Divieti P, Geller AI, Suliman G, Juppner H, Bringhurst FR: Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 2005;146:1863–1870.
7Segre BV, D’Amour P, Potts JT: Metabolism of radioiodinated bovine parathyroid hormone in the rat. Endocrinology 1976;99:1645–1652.
8Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS: Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 2006;78:1636–1643.
9D’Amour P: Acute and chronic regulation of circulating PTH: significance in health and in disease. Clin Biochem 2012;45:964–969.
10Hashizume Y, Waguri S, Watanabe T, Kominami E, Uchiyama Y: Cysteine proteinases in rat parathyroid cells with special reference to their correlation with parathyroid hormone (PTH) in storage granules. J Histochem Cytochem 1993;41:273–282.
11Berson SA, Yalow RS, Aurbach GD, Potts JT: Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci U S A 1963;49:613–617.
12Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364–1367.
13John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287–4290.
14Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y: Technical and clinical characterization of the Bio-PTH (1–84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 2004;50:385–390.
15Bikle DD: Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014;21:319–329.
16Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT Jr, Anderson RR, Blank IH, Parrish JA, Elias P: Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980;210:203–205.
17Heaney RP: Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80(6 suppl):1706S–1709S.
18Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS: Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007;103:316–321.
19Liang C, Cooke N: Vitamin D-binding protein; in Feldman D, Pike J, Glorieux F (eds): Vitamin D. San Diego, Elesevier Academic Press, 2005, pp 153–163.
20Willnow T, Nykjaer A, et al: Endocytic pathways for 25-(OH) vitamin D3; in Feldman D, Pike J, Glorieux F (eds): Vitamin D. San Diego, Elsevier Academic Press, 2005, pp 153–163.
21Haussler MR, Jurutka PW, Mizwicki M, Norman AW: Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2vitamin D3: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011;25:543–559.
22Pike JW, Meyer MB: The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 2010;39:255–269.
23Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW: The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 2004;18:2660–2671.
24Hoenderop JG, Nilius B, Bindels RJ: Calcium absorption across epithelia. Physiol Rev 2005;85:373–422.
25van de Graaf SF, Boullart I, Hoenderop JG, Bindels RJ: Regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1alpha,25-dihydroxy Vitamin D3 and dietary Ca2+. J Steroid Biochem Mol Biol 2004;89–90:303–308.
26Nordin BE, Peacock M: Role of kidney in regulation of plasma-calcium. Lancet 1969;2:1280–1283.
27Abou-Samra AB, Juppner H, Force T, Freeman MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT Jr, et al: Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A 1992;89:2732–2736.
28Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg HM, et al: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254:1024–1026.
29Hebert SC: Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996;50:2129–2139.
30Kim S, Yamazaki M, Shevde NK, Pike JW: Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. Mol Endocrinol 2007;21:197–214.
31Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA: PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004;19:235–244.
32Talmage DW, Talmage RV: Calcium homeostasis: how bone solubility relates to all aspects of bone physiology. J Musculoskelet Neuronal Interact 2007;7:108–112.